ACTEMRA 20mg/ml (400mg/20ml) price in UAE

Overview

Welcome to Dwaey, specifically on ACTEMRA 20mg/ml (400mg/20ml) Infusion/Concentrate for page.
This medicine contains an important and useful components, as it consists of Tocilizumab.
ACTEMRA 20mg/ml (400mg/20ml) is available in the market in concentration 20mg/ml and in the form of Infusion/Concentrate for.

F. HOFFMANN-LA ROCHE LTD. is the producer of ACTEMRA 20mg/ml (400mg/20ml) and it is imported from SWITZERLAND, The most popular alternatives of ACTEMRA 20mg/ml (400mg/20ml) are listed downward .

Mode Of Action

Interleukin-6 receptor antagonist; changes in clinical trials observed include decreased C-reactive protein level to within normal range, decreased values in other pharmacodynamic parameters (eg, rheumatoid factor, erythrocyte sedimentation rate, amyloid A), and increased hemoglobin value

Indication

Juvenile idiopathic arthritis
Rheumatoid Arthritis (RA)

Precaution

Serious infections leading to hospitalization or death (ie, tuberculosis; bacterial, invasive fungal, viral, or other opportunistic infections) have occurred with use Stop therapy if serious infection occurs; can restart if infection is controlled Test for latent tuberculosis before initiating; if positive, initiate tuberculosis therapy before starting tocilizumab Continue to monitor all patients for active tuberculosis during therapy Lactation: unknown whether distributed in breast milk, do not breast feed

Side Effects

>10% SC injection site reactions (7.1-10.1%) 1-10% Upper respiratory tract infections
Nasopharyngitis
Headache
Hypertension
Increased ALT
Infusion related skin reactions (eg
rash
pruritus
urticaria)
Dose related adverse reactions including decreased neutrophil count <1000/cu.mm
decreased platelets <100
000/cu.mm
Lipid elevations
Mouth ulcerations
Gastritis
Upper abdominal pain

Contra indication

Hypersensitivity

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Interactions with Other Medications and Other Forms of Interaction: Population pharmacokinetic analyses did not detect any effect of MTX, nonsteroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. Tocilizumab has not been studied in combination with other biological DMARDs. The expression of hepatic CYP450 enzymes is suppressed by cytokines, eg, IL-6, that stimulate chronic inflammation. Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, eg, tocilizumab is introduced. In vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4 enzyme expression. Tocilizumab normalizes expression of these enzymes. The effect of tocilizumab on CYP enzymes (except CYP2C19 and CYP2D6) is clinically relevant for CYP450 substrates with a narrow therapeutic index, and/or where the dose is individually adjusted. In a study in RA patients, levels of simvastatin (CYP3A4) were decreased by 57% one week following a single dose of tocilizumab, to the level similar or slightly higher than those observed in healthy subjects. When starting or stopping therapy with tocilizumab, patients taking medications, which are individually dose-adjusted and are metabolised via CYP450 3A4, 1A2, or 2C9 (eg, atorvastatin, calcium channel blockers, theophylline, warfarin, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses of these products may need to be adjusted to maintain their therapeutic effect. Given its long elimination t½, the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.